Skip to main content
Carolyn Ho, MD, Cardiology, Boston, MA

CarolynYungHoMD

Cardiology Boston, MA

Echocardiography, Cardiovascular Disease Genetics

Associate Professor of Medicine, Brigham and Women's Hospital

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ho's full profile

Already have an account?

  • Office

    75 Francis St
    Pbb 3
    Boston, MA 02115
    Phone+1 617-732-7317

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1998 - 2001
  • Harvard Medical School
    Harvard Medical SchoolClass of 1995

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2000 - 2026
  • American Board of Internal Medicine Cardiovascular Disease

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Circulating microRNAs as a Biomarker of Pediatric Hypertrophic Cardiomyopathy 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
  • The Future of HCM: new Diagnostic Tools and New Therapies 
    2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
  • Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic Cardiomyopathy 
    Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 10/13/2012

Authored Content

  • Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
  • Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
  • Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020

Press Mentions

  • Is Heart Disease Genetic?
    Is Heart Disease Genetic?January 15th, 2021
  • MAVERICK-HCM: Mavacamten Well Tolerated in Patients with Nonobstructive HCM
    MAVERICK-HCM: Mavacamten Well Tolerated in Patients with Nonobstructive HCMMarch 30th, 2020
  • MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
    MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy PatientsMarch 30th, 2020
  • Join now to see all

Grant Support

  • Using Genetics For Early Phenotyping &Prevention Of Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2010–2011
  • Diagnostic And Treatment Strategies For Preclinical HCMNational Heart, Lung, And Blood Institute2005–2009
  • Diastolic Function In Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2002–2003